Immunovant

Immunovant is a clinical-stage immunology company developing targeted therapies for people with autoimmune diseases. The firm’s primary business involves the development of monoclonal antibodies that inhibit the neonatal fragment crystallizable receptor (FcRn) to reduce levels of pathogenic immunoglobulin G (IgG) antibodies. Its lead product candidate is IMVT-1402, which is designed for subcutaneous self-administration via an autoinjector. Immunovant is also developing batoclimab, a first-generation FcRn inhibitor. These candidates are the result of a research collaboration with HanAll Biopharma; the firm holds exclusive rights to develop and commercialize these antibodies in the U.S., Canada, Mexico, the E.U., the U.K., Switzerland, the Middle East, North Africa, and Latin America. Immunovant assumed this license from Roivant Sciences in 2018 for $37.8 million and is responsible for up to $420 million in future regulatory and sales milestones, plus tiered royalties ranging from the mid-single digits to mid-teens. The firm’s pipeline addresses indications across endocrinology, neurology,...